IPP Bureau
LifeClean and Lonza Specialty Ingredients sign distribution agreement for disinfectants
By IPP Bureau - March 17, 2021
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Johnson & Johnson single-shot COVID-19 vaccine granted emergency use listing by WHO
By IPP Bureau - March 15, 2021
The vaccine was 85 percent effective in preventing severe disease across all regions.
AstraZeneca Pharma India receives approval for supplying Osimertinib in India
By IPP Bureau - March 13, 2021
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Lupin launches authorized generic version of Alinia
By IPP Bureau - March 13, 2021
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
Govt. receives 215 applications for the 36 products under PLI scheme
By IPP Bureau - March 13, 2021
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Altimmune expands AdCOVID manufacturing collaboration with Lonza
By IPP Bureau - March 13, 2021
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
UPM Biomedicals and CELLINK collaborates for 3D bioprinting developments
By IPP Bureau - March 11, 2021
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Lupin Pharma Canada announces Partnership with Endoceutics
By IPP Bureau - March 09, 2021
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
NATCO receives approval for Everolimus tablets for the US market
By IPP Bureau - March 09, 2021
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Vivimed Labs receives products approvals from Uzbekistan
By IPP Bureau - March 09, 2021
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder
By IPP Bureau - March 08, 2021
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector
By IPP Bureau - March 08, 2021
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Sun Pharma arm to acquire stake in WRS Bioproducts, Australia
By IPP Bureau - March 06, 2021
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Lupin launches penicillamine tablets USP
By IPP Bureau - March 04, 2021
Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).
COVAXIN demonstrates interim clinical efficacy of 81%
By IPP Bureau - March 04, 2021
Bharat Biotech expects to share further details of the trial results as additional data become available.
